Tarsus Pharmaceuticals, Inc.
TARS Financials — Income Statement, Margins & Balance Sheet
Revenue, net income, margins, cash and debt for TARS, built from reported filings and live market data.
Unlock Full TARS Analysis
Explore Z-Score, Smart Money signals, all timeframes and Premium indicators for TARS.
7-day free trial. No commitment during the trial.
TARS Income Statement (TTM)
- Net income (TTM)
- -$702.23M
- EPS (TTM)
- $-15.16
- Gross margin
- 93.2%
- Operating margin
- -102.5%
- Net margin
- -102.9%
- Revenue growth
- +63.9%
TARS Revenue vs Net Income by Quarter
Light bars are revenue, solid bars are net income. The gap between them is the cost of running the business — when it narrows, margins are expanding.
TARS Financial Results by Period
The last 12 reported periods for TARS, most recent first.
| Period | Revenue | Net income | Net margin | EPS |
|---|---|---|---|---|
| Q3 2026 | $194.57M | -$668.33M | -343.5% | $-14.40 |
| Q2 2026 | $173.91M | -$18.55M | -10.7% | $-0.43 |
| Q1 2026 | $162.05M | -$6.97M | -4.3% | $-0.16 |
| Q4 2025 | $151.67M | -$8.37M | -5.5% | $-0.17 |
| Q3 2025 | $118.70M | -$12.59M | -10.6% | $-0.30 |
| Q2 2025 | $102.66M | -$20.34M | -19.8% | $-0.48 |
| Q1 2025 | $78.33M | -$25.12M | -32.1% | $-0.64 |
| Q4 2024 | $66.41M | — | — | $-0.57 |
| Q3 2024 | — | — | — | $-0.61 |
| Q2 2024 | — | — | — | $-0.88 |
| Q1 2024 | $27.61M | -$35.73M | -129.4% | $-1.01 |
| Q4 2023 | $13.08M | — | — | $-1.29 |
TARS Balance Sheet & Cash Generation
Cash, debt, share count and free cash flow — the inputs that decide whether TARS can fund growth without diluting shareholders.
- Cash
- $309.61M
- Total debt
- $72.94M
- Net cash / (debt)
- $236.68M
- Shares outstanding
- 0.05B
- Free cash flow
- $69.01M
- FCF yield
- 1.8%
- Market cap
- $3.86B
- Price / sales
- 5.65x
Financials vs Valuation & Market Positioning
The statements tell you what the business earns; the multiples and Z-Score tell you what the market is currently charging for it.
- Trailing P/E
- —
- Forward P/E
- 64.99
- EPS growth
- —
- Revenue growth
- +63.9%
Z-Score readings for TARS are not available right now.
How This TARS Financial Data Is Built
Revenue, net income and EPS come from TARS's reported filings through live ZCoreAI market endpoints. Trailing twelve-month figures sum the last four reported quarters, and net margin per period is net income divided by revenue for that same period. Gross and operating margins are taken from the reported profitability block.
Cash, debt and share count come from the latest published balance sheet; where a figure is absent, free cash flow is approximated from reported net income and shares are derived from market cap divided by price. Price to sales, FCF yield and the multiples use the live quote, so they update on every page load. Nothing here is investment advice.
TARS Financials FAQ
How much revenue does TARS generate?
TARS generated roughly $682.20M of revenue over the trailing twelve months, summed from the last four reported quarters.
Is TARS profitable?
TARS runs a -102.9% net margin, equal to -$702.23M of trailing net income.
Does TARS have too much debt?
TARS carries $72.94M of total debt against $309.61M of cash, a net cash position of $236.68M. Compare that against free cash flow of $69.01M to judge how quickly it could be repaid.
What is TARS's free cash flow?
TARS generates approximately $69.01M, a 1.8% yield on the current market cap. Free cash flow is what funds buybacks, dividends and debt repayment.
Where does ZCoreAI get TARS financial data?
Revenue, net income, EPS, margins and balance sheet items come from live ZCoreAI market endpoints sourced from company filings, refreshed on every page load.
Quarterly EPS history, revenue trend and growth for TARS.
Trailing and forward multiples, PEG and earnings yield for TARS.
DCF fair value, price prediction and signal targets for TARS.
Live chart, fundamentals and valuation context for TARS.
Research tools we use
- Koyfin
Financial data, screening and market research dashboards.
- Stock Rover
Stock screening and fundamental research for dividend and value investors.
Data refreshed from live ZCoreAI market endpoints. Informational only — not investment advice.